{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:11:18Z","timestamp":1793823078842,"version":"4.6.1"},"reference-count":120,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background\/Objectives: Rhabdomyolysis, a dangerous breakdown of skeletal muscle, has been reported as an adverse event in those prescribed a statin therapy for the treatment of hypercholesterolemia. Statin drugs are some of the most prescribed treatments for elevated cholesterol levels. The purpose of this comparative study was to determine the association between the statin drugs used and the risk of rhabdomyolysis using the FDA Adverse Event Reporting System (FAERS) and transcriptomic data. Methods: A disproportionality analysis was performed to compare the risk of rhabdomyolysis between the reference statin drug (simvastatin) and the treatment group, with patient age assessed as a possible confounder. In addition, association rule mining was utilized to both identify other adverse events that frequently presented with rhabdomyolysis and identify possible drug-drug interactions (DDIs). Finally, public transcriptomic data were explored to identify the possible genetic underpinnings highlighting these differences in rhabdomyolysis risk across statins. Results: Rhabdomyolysis is a commonly reported adverse event for patients treated with statins, particularly those prescribed simvastatin. Simvastatin was associated with a more than 2-fold increased likelihood of rhabdomyolysis compared to other statins. Men were twice as likely to report rhabdomyolysis than women regardless of statin treatment, with the highest risk observed for pravastatin (ROR = 2.30, p &lt; 0.001) and atorvastatin (ROR = 2.03, p &lt; 0.0001). Several possible DDIs were identified, including furosemide\/Lasix, allopurinol clopidogrel\/Plavix, and pantoprazole, which may elevate rhabdomyolysis risk through impaired muscle function and delayed statin metabolism. Finally, nine myopathic genes were identified as possible regulators of statin-induced rhabdomyolysis, including DYSF, DES, PLEC, CAPN3, SCN4A, TNNT1, SDHA, MYH7, and PYGM in primary human muscle cells. Conclusions: Simvastatin was associated with the highest risk of rhabdomyolysis. The risk of rhabdomyolysis was more pronounced in men than women. Several possible DDIs were identified including furosemide\/Lasix, allopurinol clopidogrel\/Plavix, and pantoprazole.<\/jats:p>","DOI":"10.3390\/genes16030248","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:47:46Z","timestamp":1740109666000},"page":"248","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Association Between Statin Drugs and Rhabdomyolysis: An Analysis of FDA Adverse Event Reporting System (FAERS) Data and Transcriptomic Profiles"],"prefix":"10.3390","volume":"16","author":[{"given":"Robert","family":"Morris","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9526-3023","authenticated-orcid":false,"given":"Kun","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Mathematics & Statistics, College of Art and Science, University of South Florida, Tampa, FL 33620, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6264-3090","authenticated-orcid":false,"given":"Weiru","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Mathematics & Statistics, College of Art and Science, University of South Florida, Tampa, FL 33620, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savanah","family":"Wood","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola M.","family":"Hernandez Velez","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Ward","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariana","family":"Crescitelli","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3619-8090","authenticated-orcid":false,"given":"Feng","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Science, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33613, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"ref_1","unstructured":"Stanley, M., Chippa, V., Aeddula, N.R., Quintanilla Rodriguez, B.S., and Adigun, R. (2024). Rhabdomyolysis. StatPearls, StatPearls Publishing."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"101015","DOI":"10.1016\/j.disamonth.2020.101015","article-title":"Rhabdomyolysis","volume":"66","author":"Cabral","year":"2020","journal-title":"Dis. Mon."},{"key":"ref_3","first-page":"58","article-title":"Rhabdomyolysis: Pathogenesis, Diagnosis, and Treatment","volume":"15","author":"Torres","year":"2015","journal-title":"Ochsner J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00415-019-09185-4","article-title":"A Systematic Review on the Definition of Rhabdomyolysis","volume":"267","author":"Stahl","year":"2020","journal-title":"J. Neurol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"844","DOI":"10.12968\/bjon.2022.31.16.844","article-title":"The Management and Diagnosis of Rhabdomyolysis-Induced Acute Kidney Injury: A Case Study","volume":"31","author":"Torr","year":"2022","journal-title":"Br. J. Nurs."},{"key":"ref_6","first-page":"1","article-title":"Rhabdomyolysis: Advances in Diagnosis and Treatment","volume":"14","author":"Parekh","year":"2012","journal-title":"Emerg. Med. Pract."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2135371","DOI":"10.1001\/jamanetworkopen.2021.35371","article-title":"Trends in Use and Expenditures for Brand-Name Statins after Introduction of Generic Statins in the US, 2002\u20132018","volume":"4","author":"Lin","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.2183\/pjab.86.484","article-title":"A Historical Perspective on the Discovery of Statins","volume":"86","author":"Endo","year":"2010","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_9","first-page":"e202132","article-title":"From Fleming to Endo: The Discovery of Statins","volume":"2021","author":"Chester","year":"2021","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"ref_10","unstructured":"Sizar, O., Khare, S., Patel, P., and Talati, R. (2024). Statin Medications. StatPearls, StatPearls Publishing."},{"key":"ref_11","first-page":"373","article-title":"The Medical Expenditure Panel Survey: A National Health Information Resource","volume":"33","author":"Cohen","year":"1996","journal-title":"Inquiry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jsps.2023.04.002","article-title":"Statins Utilization Trends and Expenditures in the U.S. Before and after the Implementation of the 2013 ACC\/AHA Guidelines","volume":"31","author":"Matyori","year":"2023","journal-title":"Saudi Pharm. J."},{"key":"ref_13","unstructured":"Bansal, A.B., and Cassagnol, M. (2024). HMG-CoA Reductase Inhibitors. StatPearls, StatPearls Publishing."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Climent, E., Benaiges, D., and Pedro-Botet, J. (2021). Hydrophilic or Lipophilic Statins?. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.687585"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"f880","DOI":"10.1136\/bmj.f880","article-title":"Use of High Potency Statins and Rates of Admission for Acute Kidney Injury: Multicenter, Retrospective Observational Analysis of Administrative Databases","volume":"346","author":"Dormuth","year":"2013","journal-title":"BMJ"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Khatiwada, N., and Hong, Z. (2024). Potential Benefits and Risks Associated with the Use of Statins. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020214"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e009517","DOI":"10.1161\/JAHA.118.009517","article-title":"High-Intensity Versus Non-High-Intensity Statins in Patients Achieving Low-Density Lipoprotein Cholesterol Goal after Percutaneous Coronary Intervention","volume":"7","author":"Kim","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Sadowska, A., Osinski, P., Roztocka, A., Kaczmarz-Chojnacka, K., Zapora, E., Sawicka, D., and Car, H. (2023). Statins-from fungi to Pharmacy. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25010466"},{"key":"ref_19","first-page":"11","article-title":"Statin Induced Rhabdomyolysis","volume":"69","author":"Kumar","year":"2021","journal-title":"J. Assoc. Physicians India"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"omx104","DOI":"10.1093\/omcr\/omx104","article-title":"Statin-Induced Rhabdomyolysis: A Complication of a Commonly Overlooked Drug Interaction","volume":"2018","author":"Ezad","year":"2018","journal-title":"Oxf. Med. Case Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2015.03.005","article-title":"Successful Reintroduction of Statin Therapy after Statin-Associated Rhabdomyolysis","volume":"9","author":"Simons","year":"2015","journal-title":"J. Clin. Lipidol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1111\/bcp.15757","article-title":"Rhabdomyolysis and Statins: A Pharmacovigilance Comparative Study between Statins","volume":"89","author":"Montastruc","year":"2023","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2147\/DHPS.S333738","article-title":"A Narrative Review of Statin-Induced Rhabdomyolysis: Molecular Mechanism, Risk Factors, and Management","volume":"13","author":"Safitri","year":"2021","journal-title":"Drug Healthc. Patient Saf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"bcr2016216457","DOI":"10.1136\/bcr-2016-216457","article-title":"Statin-Associated Rhabdomyolysis Triggered by Drug-Drug Interaction with Itraconazole","volume":"2016","author":"Dybro","year":"2016","journal-title":"BMJ Case Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wei, C., Yin, W., He, Z., and Wu, B. (2023). Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System. J. Clin. Med., 12.","DOI":"10.3390\/jcm12103548"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1139\/cjpp-2024-0078","article-title":"Analysis of Literature-Derived Duplicate Records in the FDA Adverse Event Reporting System (FAERS) Database","volume":"103","author":"Han","year":"2024","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Grunwald, S.A., Popp, O., Haafke, S., Jedraszczak, N., Grieben, U., Saar, K., Patone, G., Kress, W., Steinhagen-Thiessen, E., and Dittmar, G. (2020). Statin-Induced Myopathic Changes in Primary Human Muscle Cells and Reversal by a Prostaglandin F2 Alpha Analogue. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-58668-2"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.2522\/ptj.20090251","article-title":"Effects of Statins on Skeletal Muscle: A Perspective for Physical Therapists","volume":"90","author":"MacLeod","year":"2010","journal-title":"Phys. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Vinci, P., Panizon, E., Tosoni, L.M., Cerrato, C., Pellicori, F., Mearelli, F., Biasinutto, C., Fiotti, N., Di Girolamo, F.G., and Biolo, G. (2021). Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111687"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"762","DOI":"10.2174\/0929867330666230701000400","article-title":"Association between Statins Types with Incidence of Liver Cancer: An Updated Meta-Analysis","volume":"31","author":"Zhang","year":"2024","journal-title":"Curr. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ejmech.2014.08.037","article-title":"Statins in Therapy: Understanding Their Hydrophilicity, Lipophilicity, Binding to 3-Hydroxy-3-Methylglutaryl-CoA Reductase, Ability to Cross the Blood Brain Barrier and Metabolic Stability Based on Electrostatic Molecular Orbital Studies","volume":"85","author":"Fong","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1152\/japplphysiol.01362.2011","article-title":"Coenzyme Q10 Reverses Mitochondrial Dysfunction in Atorvastatin-Treated Mice and Increases Exercise Endurance","volume":"113","author":"Muraki","year":"2012","journal-title":"J. Appl. Physiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.12659\/MSM.890777","article-title":"Coenzyme Q10 Supplementation Decreases Statin-Related mild-to-Moderate Muscle Symptoms: A Randomized Clinical Study","volume":"20","author":"Skarlovnik","year":"2014","journal-title":"Med. Sci. Monit."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin Toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4062\/biomolther.2015.089","article-title":"Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats","volume":"24","author":"Choi","year":"2016","journal-title":"Biomol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1212\/01.wnl.0000194241.35115.7c","article-title":"Coenzyme Q10 Deficiency and Isolated Myopathy","volume":"66","author":"Horvath","year":"2006","journal-title":"Neurology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1080\/00498254.2019.1662136","article-title":"The Characteristics and Mechanism of Co-Administration of Lovastatin Solid Dispersion with Kaempferol to Increase Oral Bioavailability","volume":"50","author":"Li","year":"2020","journal-title":"Xenobiotica"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.2147\/DDDT.S90016","article-title":"Improvement of Oral Bioavailability of Lovastatin by Using Nanostructured Lipid Carriers","volume":"9","author":"Zhou","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1472-8206.2004.00299.x","article-title":"Chemical, Pharmacokinetic and Pharmacodynamic Properties of Statins: An Update","volume":"19","author":"Schachter","year":"2005","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.17925\/EE.2022.18.2.89","article-title":"Statin-Related Muscle Toxicity: An Evidence-Based Review","volume":"18","author":"Jeeyavudeen","year":"2022","journal-title":"Touchreviews Endocrinol."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Murphy, C., Deplazes, E., Cranfield, C.G., and Garcia, A. (2020). The Role of Structure and Biophysical Properties in the Pleiotropic Effects of Statins. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228745"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2004.07.080","article-title":"Comparative Pharmacokinetic Interaction Profiles of Pravastatin, Simvastatin, and Atorvastatin When Coadministered with Cytochrome P450 Inhibitors","volume":"94","author":"Jacobson","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40279-017-0689-z","article-title":"Perspectives on Exertional Rhabdomyolysis","volume":"47","author":"Rawson","year":"2017","journal-title":"Sports Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/17511437211050782","article-title":"Rhabdomyolysis: An Evidence-Based Approach","volume":"23","author":"Burgess","year":"2022","journal-title":"J. Intensive Care Soc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.nmd.2021.04.007","article-title":"Risk Factors and Future Directions for Preventing and Diagnosing Exertional Rhabdomyolysis","volume":"31","author":"Carneiro","year":"2021","journal-title":"Neuromuscul. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jshs.2015.01.012","article-title":"Exercise-Induced Rhabdomyolysis Mechanisms and Prevention: A Literature Review","volume":"5","author":"Kim","year":"2016","journal-title":"J. Sport Health Sci."},{"key":"ref_47","unstructured":"Adam, M.P., Feldman, J., Mirzaa, G.M., Pagon, R.A., Wallace, S.E., and Amemiya, A. (1993). Carnitine Palmitoyltransferase II Deficiency. GeneReviews\u00ae, University of Washington."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13023-015-0264-3","article-title":"Rhabdomyolysis: A Genetic Perspective","volume":"10","author":"Scalco","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Yoon, S., Jeong, S., Jung, E., Kim, K.S., Jeon, I., Lee, Y., Cho, J.Y., Oh, W.Y., and Chung, J.Y. (2021). Effect of CYP3A4 Metabolism on Sex Differences in the Pharmacokinetics and Pharmacodynamics of Zolpidem. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-98689-z"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e89044","DOI":"10.1172\/jci.insight.89044","article-title":"Switching Harmful Visceral Fat to Beneficial Energy Combustion Improves Metabolic Dysfunctions","volume":"2","author":"Yang","year":"2017","journal-title":"JCI Insight"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Nauli, A.M., and Matin, S. (2019). Why Do Men Accumulate Abdominal Visceral Fat?. Front. Physiol., 10.","DOI":"10.3389\/fphys.2019.01486"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.hbpd.2020.03.011","article-title":"Critical Role of Estrogen in the Progression of Chronic Liver Diseases","volume":"19","author":"Ezhilarasan","year":"2020","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-3-319-70178-3_12","article-title":"Role of Estrogens in the Regulation of Liver Lipid Metabolism","volume":"1043","author":"Palmisano","year":"2017","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00003088-200039060-00002","article-title":"Clinical Pharmacokinetics of Pravastatin: Mechanisms of Pharmacokinetic Events","volume":"39","author":"Hatanaka","year":"2000","journal-title":"Clin. Pharmacokinet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.1038\/s41467-023-41552-8","article-title":"Structure of Human Drug Transporters OATP1B1 and OATP1B3","volume":"14","author":"Ciuta","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1124\/jpet.107.125831","article-title":"The Contribution of Organic Anion Transporters OAT1 and OAT3 to the Renal Uptake of Rosuvastatin","volume":"322","author":"Windass","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP Transporters on Pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"F1114","DOI":"10.1152\/ajprenal.00201.2012","article-title":"Sex-Dependent Expression of Oat3 (Slc22a8) and Oat1 (Slc22a6) Proteins in Murine Kidneys","volume":"304","author":"Breljak","year":"2013","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/hep4.1489","article-title":"Interindividual Diversity in Expression of Organic Anion Uptake Transporters in Normal and Cirrhotic Human Liver","volume":"4","author":"Taniguchi","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/clpt.2013.161","article-title":"SLCO1B1 Genetic Variant Associated with Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink","volume":"94","author":"Carr","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/bcp.13207","article-title":"Interindividual and Interethnic Variability in Drug Disposition: Polymorphisms in Organic Anion Transporting Polypeptide 1B1 (OATP1B1; SLCO1B1)","volume":"83","author":"Lee","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/FPC.0b013e3283620c3b","article-title":"OATP1B1-Related Drug-Drug and Drug-Gene Interactions as Potential Risk Factors for Cerivastatin-Induced Rhabdomyolysis","volume":"23","author":"Tamraz","year":"2013","journal-title":"Pharmacogenet. Genom."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/gim.2014.41","article-title":"Genetic Factors Affecting Statin Concentrations and Subsequent Myopathy: A HuGENet Systematic Review","volume":"16","author":"Canestaro","year":"2014","journal-title":"Genet. Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Turner, R.M., and Pirmohamed, M. (2019). Statin-Related Myotoxicity: A Comprehensive Review of Pharmacokinetic, Pharmacogenomic and Muscle Components. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010022"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e005562","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex Differences in the Use of Statins in Community Practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e231047","DOI":"10.1001\/jamanetworkopen.2023.1047","article-title":"Assessment of Sex Disparities in Nonacceptance of Statin Therapy and Low-Density Lipoprotein Cholesterol Levels Among Patients at High Cardiovascular Risk","volume":"6","author":"Brown","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ruisz, W., Stollberger, C., Finsterer, J., and Weidinger, F. (2013). Furosemide-Induced Severe Hypokalemia with Rhabdomyolysis without Cardiac Arrest. BMC Womens Health, 13.","DOI":"10.1186\/1472-6874-13-30"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/postgradmedj-2020-139701","article-title":"Diuretic-Induced Hypokalaemia: An Updated Review","volume":"98","author":"Lin","year":"2022","journal-title":"Postgrad. Med. J."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"89","DOI":"10.5414\/CNP57089","article-title":"Hypokalemic Rhabdomyolysis Aggravated by Diuretics Complicating Conn\u2019s Syndrome without Acute Renal Failure","volume":"57","author":"Ozgur","year":"2002","journal-title":"Clin. Nephrol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00421-020-04546-8","article-title":"Regulation of Muscle Potassium: Exercise Performance, Fatigue and Health Implications","volume":"121","author":"Lindinger","year":"2021","journal-title":"Eur. J. Appl. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Wang, S., Ran, Y., Chen, X., Li, C., Cheng, S., and Liu, J. (2020). Pleiotropic Effects of Simvastatin on the Regulation of Potassium Channels in Monocytes. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.00101"},{"key":"ref_72","first-page":"e52063","article-title":"Hypokalemic Periodic Paralysis Type 2 Due to SCN4A Val1105Met Mutation: A Case Study","volume":"16","author":"Hu","year":"2024","journal-title":"Cureus"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/mus.27725","article-title":"Periodic Paralysis due to Cumulative Effects of Rare Variants in SCN4A with Small Functional Alterations","volume":"66","author":"Shibano","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.freeradbiomed.2016.10.012","article-title":"Allopurinol Attenuates Rhabdomyolysis-Associated Acute Kidney Injury: Renal and Muscular Protection","volume":"101","author":"Gois","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12192-014-0543-2","article-title":"Effects of Allopurinol on Exercise-Induced Muscle Damage: New Therapeutic Approaches?","volume":"20","author":"Garatachea","year":"2015","journal-title":"Cell Stress Chaperones"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Ferrando, B., Gomez-Cabrera, M.C., Salvador-Pascual, A., Puchades, C., Derbre, F., Gratas-Delamarche, A., Laparre, L., Olaso-Gonzalez, G., Cerda, M., and Viosca, E. (2018). Allopurinol Partially Prevents Disuse Muscle Atrophy in Mice and Humans. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-21552-1"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Otani, N., Ouchi, M., Misawa, K., Hisatome, I., and Anzai, N. (2022). Hypouricemia and Urate Transporters. Biomedicines, 10.","DOI":"10.3390\/biomedicines10030652"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Hosoyamada, M. (2021). Hypothetical Mechanism of Exercise-Induced Acute Kidney Injury Associated with Renal Hypouricemia. Biomedicines, 9.","DOI":"10.3390\/biomedicines9121847"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/sj.bjp.0702789","article-title":"The Influence of Allopurinol on Kidney Haemodynamic and Excretory Responses to Renal Ischaemia in Anaesthetized Rats","volume":"128","author":"Hestin","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"ref_80","first-page":"e15018","article-title":"Acute Effects of Hypouricemia on Endothelium, Oxidative Stress, and Arterial Stiffness: A Randomized, Double-Blind, Crossover Study","volume":"9","author":"Hupkens","year":"2021","journal-title":"Physiol. Rep."},{"key":"ref_81","unstructured":"Beavers, C.J., and Naqvi, I.A. (2024). Clopidogrel. StatPearls, StatPearls Publishing."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1038\/s41467-023-38624-0","article-title":"Platelet-Derived Chemokines Promote Skeletal Muscle Regeneration by Guiding Neutrophil Recruitment to Injured Muscles","volume":"14","author":"Graca","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1345\/aph.1H394","article-title":"Clopidogrel-Precipitated Rhabdomyolysis in a Stable Heart Transplant Patient","volume":"41","author":"Burton","year":"2007","journal-title":"Ann. Pharmacother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/0971-4065.111853","article-title":"Rhabdomyolysis Induced Acute Renal Failure Secondary to Statins","volume":"23","author":"Ram","year":"2013","journal-title":"Indian J. Nephrol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/1755-5922.12028","article-title":"Epidemiology of CYP3A4-Mediated Clopidogrel Drug-Drug Interactions and Their Clinical Consequences","volume":"31","author":"Tirkkonen","year":"2013","journal-title":"Cardiovasc. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1124\/dmd.31.1.53","article-title":"The Metabolism of Clopidogrel is Catalyzed by Human Cytochrome P450 3A and Is Inhibited by Atorvastatin","volume":"31","author":"Clarke","year":"2003","journal-title":"Drug Metab. Dispos."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"D\u2019Amico, A., Cavarretta, E., Fossati, C., Borrione, P., Pigozzi, F., Frati, G., Sciarretta, S., Costa, V., De Grandis, F., and Nigro, A. (2022). Platelet Activation Favours NOX2-Mediated Muscle Damage in Elite Athletes: The Role of Cocoa-Derived Polyphenols. Nutrients, 14.","DOI":"10.3390\/nu14081558"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.avsg.2023.05.023","article-title":"Atorvastatin Effect on Clopidogrel Efficacy in Patients with Peripheral Artery Disease","volume":"95","author":"Hall","year":"2023","journal-title":"Ann. Vasc. Surg."},{"key":"ref_89","first-page":"574","article-title":"Statin and Clopidogrel Pharmacological Interaction","volume":"14","author":"Leoncini","year":"2013","journal-title":"G. Ital. Cardiol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s40265-018-0947-x","article-title":"Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins","volume":"78","author":"Danielak","year":"2018","journal-title":"Drugs"},{"key":"ref_91","first-page":"449","article-title":"Pharmacokinetic Drug Interactions with Clopidogrel: Updated Review and Risk Management in Combination Therapy","volume":"11","author":"Wang","year":"2015","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s10557-023-07459-8","article-title":"Rhabdomyolysis with Co-Administration of Statins and Antiplatelet Therapies-Analysis of the WHO Pharmacovigilance Database","volume":"38","author":"Roule","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_93","unstructured":"Bernshteyn, M.A., and Masood, U. (2024). Pantoprazole. StatPearls, StatPearls Publishing."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40264-016-0473-2","article-title":"Proton Pump Inhibitors and Risk of Rhabdomyolysis","volume":"40","author":"Duncan","year":"2017","journal-title":"Drug Saf."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1177\/10600280231156270","article-title":"Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two Different Cross-Sectional Databases","volume":"57","author":"Mitsuboshi","year":"2023","journal-title":"Ann. Pharmacother."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/jgh.16411","article-title":"A Pharmacovigilance Study of Association between Proton-Pump Inhibitors and Rhabdomyolysis Event Based on FAERS Database","volume":"39","author":"Sun","year":"2024","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1389200222666210520090632","article-title":"High-throughput LC-MS\/MS Method for Simultaneous Determination of Pantoprazole and Atorvastatin in Rat Plasma: Application to a Pharmacokinetic Interaction Study","volume":"22","author":"Le","year":"2021","journal-title":"Curr. Drug Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.bjp.0703920","article-title":"HMG-CoA Reductase Inhibitors and P-Glycoprotein Modulation","volume":"132","author":"Bogman","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1124\/dmd.113.051722","article-title":"Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions","volume":"41","author":"Shirasaka","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Miedziaszczyk, M., and Idasiak-Piechocka, I. (2023). Safety Analysis of Co-Administering Tacrolimus and Omeprazole in Renal Transplant Recipients\u2014A Review. Biomed. Pharmacother., 166.","DOI":"10.1016\/j.biopha.2023.115149"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.32.8.821","article-title":"Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities","volume":"32","author":"Li","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Andre, C., Mernissi, T., Choukroun, G., Bennis, Y., Kamel, S., Liabeuf, S., and Bodeau, S. (2021). The Prescription of Drugs That Inhibit Organic Anion Transporters 1 or 3 Is Associated with the Plasma Accumulation of Uremic Toxins in Kidney Transplant Recipients. Toxins, 14.","DOI":"10.3390\/toxins14010015"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejps.2019.03.022","article-title":"Organic Anion Transporter 3 (OAT3)-Mediated Transport of Dicaffeoylquinic Acids and Prediction of Potential Drug-Drug Interaction","volume":"133","author":"Wang","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"107647","DOI":"10.1016\/j.pharmthera.2020.107647","article-title":"Regulation of Organic Anion Transporters: Role in Physiology, Pathophysiology, and Drug Elimination","volume":"217","author":"Zhang","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1399-0004.2010.01512.x","article-title":"Desmin-Related Myopathy","volume":"80","author":"Jongbloed","year":"2011","journal-title":"Clin. Genet."},{"key":"ref_106","first-page":"245","article-title":"Panorama of the Distal Myopathies","volume":"39","author":"Savarese","year":"2020","journal-title":"Acta Myol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2147\/VHRM.S24509","article-title":"Troponin Elevation in Conditions Other Than Acute Coronary Syndromes","volume":"7","author":"Tanindi","year":"2011","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1152\/jappl.1997.83.4.1076","article-title":"Skeletal Troponin I as a Marker of Exercise-Induced Muscle Damage","volume":"83","author":"Sorichter","year":"1997","journal-title":"J. Appl. Physiol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/mus.27222","article-title":"Elevation of Fast but Not Slow Troponin I in the Circulation of Patients with Becker and Duchenne Muscular Dystrophy","volume":"64","author":"Barthel","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13023-016-0476-1","article-title":"MYH7-Related Myopathies: Clinical, Histopathological and Imaging Findings in a Cohort of Italian Patients","volume":"11","author":"Fiorillo","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s11010-023-04735-x","article-title":"MYH7 in Cardiomyopathy and Skeletal Muscle Myopathy","volume":"479","author":"Gao","year":"2024","journal-title":"Mol. Cell. Biochem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/ana.21926","article-title":"Dysferlin Overexpression in Skeletal Muscle Produces a Progressive Myopathy","volume":"67","author":"Glover","year":"2010","journal-title":"Ann. Neurol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2353\/ajpath.2009.090107","article-title":"Genetic Manipulation of Dysferlin Expression in Skeletal Muscle: Novel Insights into Muscular Dystrophy","volume":"175","author":"Millay","year":"2009","journal-title":"Am. J. Pathol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Carvalho, A.A.S., Christofolini, D.M., Perez, M.M., Alves, B.C.A., Rodart, I., Figueiredo, F.W.S., Turke, K.C., Feder, D., Junior, M.C.F., and Nucci, A.M. (2020). PYGM mRNA Expression in McArdle Disease: Demographic, Clinical, Morphological and Genetic Features. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236597"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/ene.14553","article-title":"The Etiology of Rhabdomyolysis: An Interaction between Genetic Susceptibility and External Triggers","volume":"28","author":"Kruijt","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e000151","DOI":"10.1136\/bmjsem-2016-000151","article-title":"Exertional Rhabdomyolysis: Physiological Response or Manifestation of an Underlying Myopathy?","volume":"2","author":"Scalco","year":"2016","journal-title":"BMJ Open Sport Exerc. Med."},{"key":"ref_117","first-page":"85","article-title":"LPIN1 Deficiency with Severe Recurrent Rhabdomyolysis and Persistent Elevation of Creatine Kinase Levels due to Chromosome 2 Maternal Isodisomy","volume":"5","author":"Meijer","year":"2015","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ajhg.2008.09.002","article-title":"Mutations in LPIN1 Cause Recurrent Acute Myoglobinuria in Childhood","volume":"83","author":"Zeharia","year":"2008","journal-title":"Am. J. Hum. Genet."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/jnen\/nly042","article-title":"Sdha+\/\u2212 Rats Display Minimal Muscle Pathology Without Significant Behavioral or Biochemical Abnormalities","volume":"77","author":"Siebers","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1365-2125.2011.03907.x","article-title":"What Is a Relevant Statin Concentration in Cell Experiments Claiming Pleiotropic Effects?","volume":"72","author":"Lindh","year":"2011","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/3\/248\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:39:25Z","timestamp":1760027965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/3\/248"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":120,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["genes16030248"],"URL":"https:\/\/doi.org\/10.3390\/genes16030248","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}